Effects of antipsychotic treatment on cognition in healthy subjects

Journal of Psychopharmacology

Volumn 27, Issue 4, 2013, Pages 374-385

  Veselinović, Tanja ^a,b   Schorn, Holger ^a,b   Vernaleken, Ingo B ^a,b   Hiemke, Christoph ^d   Zernig, Gerald ^e   Gur, Ruben ^c   Gründer, Gerhard ^a,b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b Julich Aachen Research Alliance JARA   (Germany)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

aripiprazole; cognition; Dopamine; haloperidol; reserpine

Indexed keywords

ARIPIPRAZOLE; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; PLACEBO; RESERPINE;

ADULT; ALERTNESS; ARTICLE; ATTENTION; COGNITION; CONTROLLED STUDY; DIGIT SYMBOL SUBSTITUTION TEST; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; HUMAN EXPERIMENT; LEARNING; MALE; MENTAL PERFORMANCE; NEUROMODULATION; NEUROPSYCHOLOGICAL TEST; NORMAL HUMAN; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPONSE TIME; SINGLE BLIND PROCEDURE; TEST FOR ATTENTIONAL PERFORMANCE; VISUAL ANALOG SCALE;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ANTIPSYCHOTIC AGENTS; ATTENTION; BRAIN; COGNITION; COGNITION DISORDERS; DOPAMINE ANTAGONISTS; FEMALE; HALOPERIDOL; HUMANS; LEARNING; MALE; MIDDLE AGED; NEURONS; PIPERAZINES; QUINOLONES; REACTION TIME; RESERPINE; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84875730174     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112466183     Document Type: Article

References (56)

1. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989 ; 154: 672-676
2. Barrett S L, Bell R, Watson D, et al. Effects of amisulpride, risperidone and chlorpromazine on auditory and visual latent inhibition, prepulse inhibition, executive function and eye movements in healthy volunteers. J Psychopharmacol. 2004 ; 18: 156-172
3. Buchanan RW, Freedman R, Javitt DC, et al. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull. 2007 ; 33: 1120-1130
4. Cools R, Robbins TW. Chemistry of the adaptive mind. Philos Trans Roy Soc A. 2004 ; 362: 2871-2888
5. Davidson M, Galderisi S, Weiser M, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry. 2009 ; 166: 675-682
6. Davies MA, Sheffler DJ, Roth BL. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 2004 ; 10: 317-336
7. De Bruijn ER, Sabbe BG, Hulstijn W, et al. Effects of antipsychotic and antidepressant drugs on action monitoring in healthy volunteers. Brain Res. 2006 ; 1105: 122-129
8. Deslauriers J, Lefrançois M, Larouche A, et al. Antipsychotic-induced DRD2 upregulation and its prevention by α-lipoic acid in SH-SY5Y neuroblastoma cells. Synapse. 2011 ; 65: 321-331
9. Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry. 2007 ; 64: 532-542
10. First MB, Spitzer RL, Williams JBW Structured clinical interview for DSM-IV - clinical version (SCID-CV) (User's Guide and Interview). Washington, DC: American Psychiatric Press, Inc ; 1997 :
11. Gold JM, Carpenter C, Randolph C, et al. Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry. 1997 ; 54: 159-165
12. Goldberg TE, Weinberger DR. Genes and the parsing of cognitive processes. Trends Cogn Sci. 2004 ; 8: 325-335
13. Goldman-Rakic PS. Regional and cellular fractionation of working memory. Proc Natl Acad Sci U S A. 1996 ; 93: 13,473-13,480
14. Goldman-Rakic PS, Muly EC, Williams GV. D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev. 2000 ; 31: 295-301
15. Gray JA, Roth BL. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull. 2007 ; 33: 1100-1119
16. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry. 1996 ; 153: 321-330
17. Gründer G, Fellows C, Janouschek H, et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am J Psychiatry. 2008 ; 165: 988-995
18. Gründer G, Hippius H, Carlsson A. The 'atypicality' of antipsychotics: a concept re-examined and re-defined. Nat Rev Drug Discov. 2009 ; 8: 197-202
19. Hawkins KA, Addington J, Keefe RS, et al. Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophr Res. 2004 ; 67: 115-122
20. Henry JP, Sagné C, Bedet C, et al. The vesicular monoamine transporter: from chromaffin granule to brain. Neurochem Int. 1998 ; 32: 227-246
21. Hill SK, Beers SR, Kmiec JA, et al. Impairment of verbal memory and learning in antipsychotic-naïve patients with first-episode schizophrenia. Schizophr Res. 2004 ; 68: 127-136
22. Kahn RS, Harvey PD, Davidson M, et al. Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function. Schizophr Res. 1994 ; 11: 217-224
23. Kannari K, Tanaka H, Maeda T, et al. Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation. J Neurochem. 2000 ; 74: 263-269
24. Kim JH, Son YD, Kim HK, et al. Antipsychotic-associated mental side effects and their relationship to dopamine D2 receptor occupancy in striatal subdivisions: a high-resolution PET study with [11C]raclopride. J Clin Psychopharmacol. 2011 ; 31: 507-511
25. Knowles EE, David AS, Reichenberg A. Processing speed deficits in schizophrenia: reexamining the evidence. Am J Psychiatry. 2010 ; 167: 828-835
26. Kortte KB, Horner MD, Windham WK. The trail making test, part B: cognitive flexibility or ability to maintain set?. Appl Neuropsychol. 2002 ; 9: 106-109
27. Lehrl S Mehrfachwahl-Wortschatz-Intelligenztest MWTB. Balingen: Perimed-Spitta ; 1995 :
28. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011 ; 306: 1359-1369
29. Maher AR, Theodore G. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J Manag Care Pharm. 2012 ; 18 (5 Suppl B). 1-20
30. Marder SR, Fenton W. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. Schizophr Res. 2004 ; 72: 5-9
31. Marsh-Richard DM, Hatzis ES, Mathias CW, et al. Adaptive Visual Analog Scales (AVAS): a modifiable software program for the creation, administration, and scoring of visual analog scales. Behav Res Methods. 2009 ; 41: 99-106
32. McCann UD, Penetar DM, Shaham Y, et al. Effects of catecholamine depletion on alertness and mood in rested and sleep deprived normal volunteers. Neuropsychopharmacology. 1993 ; 8: 345-356
33. Niendam TA, Bearden CE, Rosso IM, et al. A prospective study of childhood neurocognitive functioning in schizophrenic patients and their siblings. Am J Psychiatry. 2003 ; 160: 2060-2062
34. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol. 2002 ; 67: 53-83
35. Nordström AL, Farde L, Halldin C. Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl). 1992 ; 106: 433-438
36. Owen AM, Iddon JL, Hodges JR, et al. Spatial and non-spatial working memory at different stages of Parkinson's disease. Neuropsychologia. 1997 ; 35: 519-532
37. Ramaekers JG, Louwerens JW, Muntjewerff ND, et al. Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. J Clin Psychopharmacology. 1999 ; 19: 209-221
38. Rémillard S, Pourcher E, Cohen H. Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia. J Int Neuropsychol Soc. 2008 ; 14: 110-118
39. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov. 2004 ; 3: 353-359
40. Royer FL, Gilmore GC, Gruhn JJ. Normative data for the Symbol Digit Substitution Task. J Clin Psychol. 1981 ; 37: 608-614
41. Saeedi H, Remington G, Christensen BK. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophr Res. 2006 ; 85: 222-231
42. Sakurai H, Bies RR, Stroup ST, et al. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE Data. Schizophr Bull. 2012 2012 ;:
43. Schear JM, Sato SD. Effects of visual acuity and visual motor speed and dexterity on cognitive test performance. Arch Clin Neuropsychol. 1989 ; 4: 25-32
44. Schück S, Bentué-Ferrer D, Kleinermans D, et al. Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers. Fundam Clin Pharmacol. 2002 ; 16: 57-65
45. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970 ; 212: 11-19
46. Sturm W, Willmes K, Orgass B, et al. Do specific attention deficits need specific training?. Neuropsychol Rehabil. 1997 ; 8: 81-103
47. Uchida H, Rajji TK, Mulsant BH, et al. D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. J Clin Psychopharmacol. 2009 ; 29: 571-575
48. Vernaleken I, Kumakura Y, Buchholz HG, et al. Baseline [18F] -FDOPA kinetics are predictive of haloperidol-induced changes in dopamine turnover and cognitive performance: A positron emission tomography study in healthy subjects. Neuroimage. 2008 ; 40: 1222-1231
49. Vernaleken I, Kumakura Y, Cumming P, et al. Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. Neuroimage. 2006 2006 ; 30: 1332-1339
50. Veselinović T, Schorn H, Vernaleken IB, et al. Impact of different antidopaminergic mechanisms on the dopaminergic control of prolactin secretion. J Clin Psychopharmacol. 2011a ; 31: 214-220
51. Veselinović T, Schorn H, Vernaleken I, et al. Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo controlled study in healthy volunteers. Psychopharmacology (Berl). 2011b ; 218: 733-748
52. Wechsler D Wechsler Adult Inteligence Scale-III (WAIS-III) manual. New York: The Psychological Corporation ; 1997 :
53. Weinberger DR, Berman KF, Chase TN. Mesocortical dopaminergic function and human cognition. Ann N Y Acad Sci. 1988 ; 537: 330-338
54. Wise RA. Dopamine, learning and motivation. Nat Rev Neurosci. 2004 ; 5: 483-494
55. Yang YK, Yeh TL, Chiu NT, et al. Association between cognitive performance and striatal dopamine binding is higher in timing and motor tasks in patients with schizophrenia. Psychiatry Res. 2004 ; 131: 209-216
56. Zimmermann P, Fimm B Testbatterie zur Erfassung von Aufmerksamkeitsstörungen. Version 1.02. Freiburg: Psytest ; 1993 :